US 11,883,497 B2
Lymphatic system-directing lipid prodrugs
Daniel Kenneth Bonner, Sharon, MA (US); Ketki Karanam, Newton, MA (US); James T. Mutamba, Newton, MA (US); Rishab R. Shyam, Arlington, MA (US); Jamie Simpson, Chestnut Hill, MA (US); Sifei Han, Bundoora (AU); Luojuan Hu, Bundoora (AU); Christopher John Hamilton Porter, South Melbourne (AU); Tim Quach, Southbank (AU); and Natalie Trevaskis, Newington (AU)
Assigned to PureTech LYT, Inc., Boston, MA (US); and Monash University, Clayton (AU)
Appl. No. 16/642,794
Filed by PureTech LYT, Inc., Boston, MA (US); and Monash University, Clayton (AU)
PCT Filed Aug. 29, 2018, PCT No. PCT/US2018/048642
§ 371(c)(1), (2) Date Feb. 27, 2020,
PCT Pub. No. WO2019/046491, PCT Pub. Date Mar. 7, 2019.
Claims priority of provisional application 62/551,627, filed on Aug. 29, 2017.
Claims priority of provisional application 62/607,700, filed on Dec. 19, 2017.
Claims priority of provisional application 62/607,749, filed on Dec. 19, 2017.
Claims priority of provisional application 62/714,029, filed on Aug. 2, 2018.
Claims priority of provisional application 62/724,274, filed on Aug. 29, 2018.
Claims priority of provisional application 62/724,440, filed on Aug. 29, 2018.
Prior Publication US 2022/0001015 A1, Jan. 6, 2022
Int. Cl. A61K 45/06 (2006.01); A61K 47/54 (2017.01)
CPC A61K 47/543 (2017.08) [A61K 45/06 (2013.01)] 10 Claims
 
1. A compound of Formula X-b:

OG Complex Work Unit Chemistry
wherein:
R1 and R2 are each independently hydrogen or —C(O)R3;
each R3 is independently a saturated or unsaturated, straight or branched, optionally substituted C1-37 hydrocarbon chain;
each R4 is independently hydrogen or a C1-6 aliphatic group;
-M- is

OG Complex Work Unit Chemistry
 and
A is a therapeutic agent.